Detalles de la búsqueda
1.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 25(5): 563-571, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38621400
2.
Risk stratification in the investigation of pulmonary nodules in a high-risk cohort: positron emission tomography/computed tomography outperforms clinical risk prediction algorithms.
Intern Med J
; 47(12): 1385-1392, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28782248
3.
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med
; 61(6): 857-865, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31732676
4.
Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.
J Nucl Med
; 60(4): 517-523, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30291192
5.
Optical differentiation between malignant and benign lymphadenopathy by grey scale texture analysis of endobronchial ultrasound convex probe images.
Chest
; 141(3): 709-715, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21885729
6.
Tumor thrombus in the great veins from papillary carcinoma of the thyroid: 131I scan findings.
J Clin Endocrinol Metab
; 95(6): 2527-8, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20525903
Resultados
1 -
6
de 6
1
Próxima >
>>